YCR013C Antibody

What is YCR013C and why are antibodies against it valuable for yeast research?

YCR013C is a systematic gene designation in Saccharomyces cerevisiae (budding yeast). Antibodies targeting this protein enable detection, quantification, and localization of the gene product in various experimental settings. These antibodies function through specific binding of their variable domains and complementarity-determining regions (CDRs) to epitopes on the YCR013C protein .

The value of these antibodies stems from their ability to:

• Enable protein expression monitoring via western blotting

• Support protein-protein interaction studies through immunoprecipitation

• Facilitate subcellular localization using immunofluorescence microscopy

• Allow chromatin association studies if the protein interacts with DNA

• Support protein purification through immunoaffinity techniques

Antibody development requires careful consideration of epitope selection, immunization strategies, and rigorous validation procedures to ensure specificity and reproducibility in yeast research applications.

How should I validate the specificity of a YCR013C antibody?

Validation of YCR013C antibodies requires a comprehensive approach to ensure experimental reliability:

• Genetic validation: Test the antibody in YCR013C deletion strains, where signal absence confirms specificity

• Overexpression validation: Examine signal intensity in strains overexpressing the protein

• Multiple epitope targeting: Compare antibodies recognizing different regions of YCR013C

• Cross-reactivity assessment: Test against related yeast proteins to confirm specificity

• Orthogonal validation: Compare with tagged versions of YCR013C (e.g., GFP-tagged)

These methodologies align with best practices in antibody research described in the Patent and Literature Antibody Database (PLAbDab), which emphasizes thorough validation to ensure antibody specificity . Validation should include western blotting, immunoprecipitation, and application-specific tests to evaluate the antibody's performance in your specific experimental context.

What epitope selection strategies yield the most effective YCR013C antibodies?

Effective epitope selection for YCR013C antibodies should follow these methodological approaches:

• Structural analysis: Target surface-exposed regions with high predicted antigenicity

• Hydrophilicity assessment: Focus on hydrophilic regions that are likely accessible in native conditions

• Conservation mapping: Identify unique regions if specificity against related proteins is required

• Functional domain consideration: Either target or avoid functional domains based on research objectives

• Secondary structure evaluation: Prefer regions with stable secondary structures

These strategies should be complemented by computational prediction tools to identify potential epitopes. The effectiveness of specific binding motifs has been demonstrated in other systems, such as the YYDRxG motif in SARS-CoV-2 antibodies, which facilitates targeting of functionally conserved epitopes . Similar structural features could potentially be identified for optimal YCR013C antibody design.

What experimental applications are most suited for YCR013C antibodies?

YCR013C antibodies can be employed in multiple experimental applications, each requiring specific optimization:

The effectiveness of each application depends on the antibody's specific characteristics, including its complementarity-determining regions (CDRs) that form the antigen-binding site . These regions determine the antibody's affinity and specificity for the YCR013C protein, directly impacting experimental success.

How can I optimize immunoprecipitation protocols for YCR013C under different yeast growth conditions?

Optimizing immunoprecipitation (IP) for YCR013C requires methodical adjustment based on specific growth conditions:

• Lysis buffer optimization:

  • For vegetative growth: Use 50mM Tris-HCl (pH 7.5), 150mM NaCl, 0.1% NP-40 with protease inhibitors

  • For stress conditions: Increase detergent concentration to 0.5% NP-40 and add phosphatase inhibitors

  • For stationary phase: Add higher concentration of protease inhibitors to combat increased proteolytic activity

• Cell disruption methods by growth phase:

  • Log phase: Standard glass bead lysis (8 cycles of 30 seconds)

  • Post-diauxic shift: Extended disruption time (12 cycles)

  • Stationary phase: Combined mechanical and enzymatic lysis

• Antibody coupling strategies:

  • Direct coupling to beads (5-10μg antibody per 50μl bead slurry)

  • Pre-clearing lysates with naked beads to reduce background

  • Sequential IP for complex purification

• Washing optimization:

  • Low stringency: 150mM NaCl for weak interactions

  • Medium stringency: 300mM NaCl for standard purification

  • High stringency: 500mM NaCl for specific interactions

Understanding the structure of antibodies, particularly how their variable domains and CDRs interact with antigens, explains why optimization of binding conditions significantly impacts immunoprecipitation success .

What approaches work best for developing YCR013C-specific nanobodies for advanced imaging applications?

Developing YCR013C-specific nanobodies requires several methodological considerations:

• Selection platform options:

  • Phage display libraries offer high-throughput screening capabilities

  • Camelid immunization provides strong binders but requires longer development time

  • Synthetic libraries allow for rapid development with customizable properties

• Design and development workflow:

  • Antigen preparation using recombinant YCR013C protein

  • Library construction and selection against purified target

  • Enrichment through multiple rounds of panning

  • Sequence analysis to identify conserved binding motifs

  • Expression and purification of selected nanobodies

• Computational design strategies:

  • Structure prediction using AlphaFold-Multimer

  • Binding interface optimization via Rosetta

  • Integration of protein language models like ESM for sequence optimization

• Validation for imaging applications:

  • Direct fluorophore conjugation for live-cell imaging

  • Penetration efficiency in spheroplasted yeast

  • Comparison with conventional antibodies for signal-to-noise ratio

This approach parallels the Virtual Lab methodology used for SARS-CoV-2 nanobody design, which employed computational tools to develop nanobodies with specific binding properties . Similar computational approaches could be adapted for designing nanobodies against YCR013C.

How can I implement ChIP-seq experiments using YCR013C antibodies to study chromatin associations?

For successful ChIP-seq experiments with YCR013C antibodies, implement this methodological workflow:

• Cross-linking optimization:

  • Standard condition: 1% formaldehyde for 10 minutes

  • For weak interactions: Extend to 15-20 minutes

  • For transient interactions: Use dual cross-linkers (formaldehyde plus DSG)

• Chromatin fragmentation protocol:

  • Sonication parameters: 30 seconds ON/30 seconds OFF, 10-15 cycles

  • Target fragment size: 200-500bp (verify by gel electrophoresis)

  • Enzymatic fragmentation alternative: MNase digestion for 5-15 minutes

• IP conditions:

  • Antibody amount: 2-10μg per reaction (titrate for optimal signal-to-noise)

  • Incubation: 4°C overnight with rotation

  • Wash stringency: Gradual increase in salt concentration (150mM to 500mM NaCl)

• Quality control metrics:

  Metric	Acceptable Value	Method of Assessment
  Enrichment	>4-fold over background	qPCR at known targets
  FRiP score	>1%	Bioinformatic analysis
  IDR	<0.05	Comparison between replicates
  Library complexity	>10 million unique fragments	Bioinformatic analysis

• Data analysis pipeline:

  • Peak calling using MACS2

  • Motif discovery with MEME/HOMER

  • Genome browser visualization

  • Integration with RNA-seq or proteomics data

The structure of antibodies, particularly their CDRs and hypervariable regions, explains why some antibodies perform better than others in ChIP applications .

How can I troubleshoot conflicting results between different batches of YCR013C antibodies?

When encountering inconsistent results between antibody batches, implement this systematic troubleshooting approach:

• Validation comparison matrix:

  Validation Method	Batch A	Batch B	Interpretation
  Western blot band size	Single band at expected MW	Multiple bands	Batch B may have lower specificity
  Signal in knockout strain	No signal	Weak signal	Batch B shows cross-reactivity
  IP-mass spec	YCR013C as top hit	Poor enrichment	Batch A has better affinity
  Immunofluorescence	Nuclear signal	Diffuse signal	Different epitope accessibility

• Epitope mapping:

  • Perform epitope mapping to determine if batches target different regions

  • Use peptide competition assays to confirm epitope specificity

  • Consider structural changes in the protein that might affect epitope accessibility

• Antibody characterization:

  • Determine antibody concentration via protein assay

  • Assess antibody purity through SDS-PAGE

  • Check isotype and species to confirm consistency

• Standardization protocol:

  • Normalize antibody concentrations

  • Use reference samples across experiments

  • Implement positive control samples

The variability in antibody performance often relates to differences in the complementarity-determining regions (CDRs) that determine binding specificity, as described in literature on antibody structure .

What are the optimized protocols for using YCR013C antibodies in super-resolution microscopy?

For optimal use of YCR013C antibodies in super-resolution microscopy:

• Sample preparation optimization:

  • Fixation: 4% PFA for 15 minutes at room temperature

  • Spheroplasting: 10 units zymolyase/OD600 for 15 minutes

  • Permeabilization: 0.1% Triton X-100 for 10 minutes

  • Blocking: 5% BSA for 1 hour

• Antibody selection and modification:

  • Use Fab fragments (55kDa vs. 150kDa) to decrease linkage error

  • Consider direct conjugation to photoswitchable fluorophores

  • Select bright, photostable dyes (Alexa647, Janelia Fluor dyes)

• Super-resolution technique comparison:

  Technique	Resolution	Antibody Requirements	Best Application
  STORM/PALM	10-30nm	Photoswitchable dyes	Highest resolution protein mapping
  STED	30-70nm	Photostable dyes	Live cell potential with minimal modifications
  SIM	100-120nm	Standard fluorophores	Live cell compatible with standard probes
  Expansion microscopy	~70nm	Resists denaturation	Complex structures with multiple proteins

• Protocol adaptations for yeast cells:

  • Cell wall removal: Complete spheroplasting is critical

  • Cell immobilization: ConA or poly-L-lysine coated coverslips

  • Buffer optimization: Higher refractive index matching for yeast

  • Mounting media: Specialized for photoswitching dyes

The information about antibody structure, particularly the size and configuration of the variable domains and CDRs , explains why smaller antibody fragments improve resolution in super-resolution microscopy by decreasing the distance between the fluorophore and the target.

How can I develop a quantitative ELISA for measuring YCR013C protein levels in yeast lysates?

Developing a quantitative ELISA for YCR013C requires methodical optimization:

• ELISA format selection:

  • Sandwich ELISA: Requires two antibodies binding different epitopes

  • Indirect ELISA: Single antibody, potentially higher background

  • Competitive ELISA: Useful when limited epitopes are available

• Protocol optimization steps:

  • Capture antibody concentration: Titrate from 1-10μg/ml

  • Blocking agent: Test BSA vs. casein vs. commercial blockers

  • Sample preparation: Optimize lysis buffer composition

  • Detection system: HRP vs. AP conjugates

• Standard curve development:

  • Use recombinant YCR013C or tagged protein expressed in yeast

  • Prepare 7-point standard curve with 2-fold dilutions

  • Include blank and zero standard controls

• Validation parameters:

  Parameter	Acceptance Criteria	Method of Assessment
  Specificity	No signal in knockout	Test knockout lysates
  Sensitivity	LLOQ < expected concentration	Dilution series
  Precision	CV < 15%	Replicates (n=6)
  Linearity	R² > 0.98	Dilution series analysis
  Recovery	80-120%	Spike-in experiments

• Quality control implementation:

  • Include reference sample in each plate

  • Monitor inter-assay CV

  • Implement Levey-Jennings charts for trend analysis

Similar principles have been used in developing quantitative assays for antibodies against other proteins, as demonstrated in literature on antibody methodologies .

What computational tools can enhance the design and application of YCR013C antibodies?

Leveraging computational tools for YCR013C antibody research involves:

• Structure and epitope prediction:

  • Protein structure prediction: AlphaFold2 for YCR013C structure

  • Epitope mapping: BepiPred, DiscoTope for B-cell epitope prediction

  • Antibody modeling: Rosetta Antibody for structure prediction

  • Binding simulation: Molecular dynamics for antibody-antigen interactions

• Experimental design optimization:

  • Design of Experiments (DoE) for protocol parameter optimization

  • Statistical power analysis for sample size determination

  • Machine learning for protocol optimization

• Data analysis tools by application:

  Application	Recommended Tools	Key Functions
  Microscopy	CellProfiler, ImageJ	Automated image quantification, colocalization analysis
  Proteomics	MaxQuant, Skyline	IP-MS data analysis, protein quantification
  ChIP-seq	MACS2, HOMER	Peak calling, motif discovery
  ELISA	5-PL curve fitting	Accurate concentration determination

• Integrated approaches:

  • Virtual experimental planning

  • In silico validation of antibody specificity

  • AI-guided antibody engineering

  • Computational nanobody design

The Virtual Lab approach described for SARS-CoV-2 nanobody design demonstrates how AI agents can develop novel antibodies using computational tools like ESM, AlphaFold-Multimer, and Rosetta . Similar approaches could enhance YCR013C antibody development through computational optimization of binding properties.

How can I use YCR013C antibodies to investigate protein-protein interactions across different yeast growth phases?

For investigating YCR013C protein interactions across growth phases:

• Optimized co-immunoprecipitation by growth phase:

  Growth Phase	Lysis Method	Buffer Modifications	Special Considerations
  Log phase	Mechanical disruption	Standard IP buffer	Capture rapid interactions
  Diauxic shift	Spheroplasting	Add phosphatase inhibitors	Monitor PTM-dependent interactions
  Stationary	Extended bead beating	Increase detergent	Address aggregation issues
  Stress response	Gentle lysis	Add stabilizing agents	Preserve stress granules

• Cross-linking optimization:

  • Implement gradient cross-linking (0.1-3% formaldehyde)

  • Use membrane-permeable cross-linkers for internal complexes

  • Consider MS-compatible cross-linkers for direct interaction mapping

• Proximity-based interaction methods:

  • BioID fusion to YCR013C for proximity labeling

  • APEX2 for rapid proximity labeling

  • Split-reporter systems with candidate interactors

• Temporal resolution approaches:

  • Time-course experiments with synchronized cultures

  • Rapid sample collection with flash-freezing

  • Live-cell imaging with fluorescently tagged proteins

• Validation framework:

  • Reciprocal co-IPs

  • Yeast two-hybrid confirmation

  • Functional assays to test biological relevance

The structure of antibodies, with their Fc regions that can bind to various receptors , impacts their performance in co-immunoprecipitation experiments, particularly when using different buffer conditions or detergents.

What methods can be used to develop YCR013C antibodies with enhanced specificity for variant detection?

Developing highly specific YCR013C antibodies for variant detection requires:

• Enhanced screening strategies:

  • Deep sequencing of antibody libraries

  • Negative selection against related proteins

  • Competitive elution with variant-specific peptides

  • High-throughput affinity and specificity screening

• Epitope-focused design:

  • Target regions with known variant-specific sequences

  • Structure-guided epitope selection

  • Design antibodies against transition states or conformational epitopes

  • Focus on regions undergoing post-translational modifications

• Advanced engineering approaches:

  • CDR optimization through directed evolution

  • Framework modifications for stability

  • Phage display with stringent selection conditions

  • Yeast display with fluorescence-activated cell sorting

• Validation for variant discrimination:

  Validation Approach	Methodology	Expected Outcome
  Peptide arrays	Test binding to variant peptides	Binding specificity profile
  Surface plasmon resonance	Measure kinetics for variants	Affinity differences between variants
  Mutant yeast strains	Test in strains expressing variants	In vivo specificity confirmation
  Western blot panel	Blot against variant samples	Visual confirmation of specificity

Similar principles to those used in developing antibodies with the YYDRxG motif for SARS-CoV-2 variant recognition could be applied to YCR013C antibody development .

How can I implement multiplex detection systems using YCR013C antibodies alongside other yeast protein markers?

For implementing multiplex detection of YCR013C with other proteins:

• Platform selection by application needs:

  • Bead-based systems (Luminex) for high multiplexing capability

  • Planar arrays for spatial resolution

  • Microfluidic systems for minimal sample consumption

  • Digital platforms for absolute quantification

• Antibody panel development:

  • Cross-reactivity elimination through careful antibody selection

  • Optimization of antibody pairs for balanced sensitivity

  • Concentration matching for uniform detection limits

• Protocol optimization steps:

  Component	Optimization Parameter	Approach
  Capture antibodies	Coupling density	Titration (50-100μg/ml)
  Detection antibodies	Concentration	Checkerboard titration
  Sample preparation	Buffer composition	Matrix compatibility testing
  Signal development	Incubation time	Time course optimization
  Data acquisition	Instrument settings	Standard curve linearity

• Data analysis and interpretation:

  • Implement standard curve fitting for each analyte

  • Establish dynamic range and detection limits

  • Create visualization tools for pattern recognition

  • Apply statistical methods for pathway analysis

• Quality control framework:

  • Include internal control proteins

  • Monitor inter-assay variation

  • Implement spike recovery for matrix effects

Understanding antibody structure, particularly the complementarity-determining regions (CDRs) , helps explain why careful antibody selection is critical for developing multiplex assays without cross-reactivity issues.